EKF Diagnostics Investor Announcements
EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.
Data presented for sTNFR1 at ASN, San Diego.
The Board note the announcement by Jinjing (Group) Co., Ltd. that they do not intend to make an offer for the Company.
The Board note the announcement by Jinjing (Group) Co., Ltd. that they do not intend to make an offer for the Company.
The deadline for Jinjing has been extended to 5pm on 19 October 2015.
The deadline for Jinjing has been extended to 5pm on 23rd October 2015.
EKF announces that results from a study involving EKF Molecular’s PointMan™ DNA enrichment technology have been published in Clinical Cancer Research.
Study using PointMan DNA enrichment technology have been accepted for publication in Clinical Cancer Research.
Newsletter
Keep up to date with all our activities, events, exhibitions, promotions, investor news & more.